Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Chih Wan Goh"'
Publikováno v:
Precision Medical Sciences, Vol 13, Iss 2, Pp 99-106 (2024)
Abstract p95HER2 isoform is a truncated form of HER2 that retains the C terminal domain but lacks an N terminal trastuzumab binding site. From 2014 to 2016, we assessed the expression of p95HER2 expression in 59 HER2‐positive breast cancer patients
Externí odkaz:
https://doaj.org/article/7a951ce7c1964f599d6ca482e974327a
Autor:
Chih Wan Goh, Wei-Ru Chi, Liyi Zhang, Qi Zhang, Ming Chen, Min Xiong, Douwaner Liu, Hengyu Ren, Bingqiu Xiu, Jingyan Xue, Yayun Chi, Jiong Wu
Publikováno v:
Cancer Research. 83:P1-13
Background: -Trastuzumab-based neoadjuvant chemotherapy has shown to have remarkable clinical benefits for HER2-positive breast cancer patients who had higher tumor burden. -Patients who achieved pathological complete response (pCR) are known to have
Autor:
Liyi Zhang, Qi Zhang, Pei Li, Min Xiong, Yue Zhou, Jingyan Xue, Ming Chen, Wei-Ru Chi, Hengyu Ren, Chih Wan Goh, Douwaner Liu, Liren Wangxu, Yayun Chi, Bingqiu Xiu, Jiong Wu
Publikováno v:
Cancer Research. 83:P3-05
ABSTRACT Background: Breast cancer has become the most common cancer worldwide and triple-negative breast cancer (TNBC) is the most aggressive subtype due to the lacks of hormone receptors and HER2 expression. Increasing rate of breast cancer metasta
Autor:
Chih Wan Goh, Liyi Zhang, Wei-Ru Chi, Bingqiu Xiu, Jiajian Chen, Wenqing Yang, Chunxia Ao, Jianxing Tang, Jingyan Xue, Yayun Chi, Jiong Wu
Publikováno v:
Cancer Research. 83:P5-02
Background: -HER2-positive breast cancer subtype accounted for around 15-20% of all breast cancer. -The introduction of HER2-targeted therapy such as trastuzumab and pertuzumab has remarkably increased the patients’ prognosis of HER2-positive breas
Autor:
Kunwei Shen, Yafen Li, Li Zhu, Ou Huang, Caijin Lin, Weiguo Chen, Shuning Ding, Xiaosong Chen, Jiayi Wu, Chih Wan Goh
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 145:1877-1886
Ductal carcinoma in situ (DCIS) is widely recognized as the precursor of invasive ductal carcinoma (IDC). We aimed to analyze the clinicopathological characteristics and clinical outcomes of coexisting DCIS component in IDC and its clinical significa